$303.00
1.55%
NYSE, Oct 05, 04:00 pm EDT. Closed.
ISIN
US5367971034
Symbol
LAD

Lithia Motors, Inc. Class A Stock News

Neutral
●
GlobeNewsWire
●
27 days ago
MEDFORD, Ore., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced the acquisition of Rockwall Hyundai in Rockwall, Texas, as part of the company's continued strategic network expansion and brings an estimated $75 million in annualized revenue.
Neutral
●
GlobeNewsWire
●
about one month ago
MEDFORD, Ore., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced the company is investing $500,000 in more than 200 nonprofit youth and community organizations nationwide through its Lithia4Kids Community Giving Grants, a program that partners with organizations dedicated to educating and strengthening the communities Lithia & Driveway serves. The grants will supp...
Neutral
●
GlobeNewsWire
●
about one month ago
MEDFORD, Ore., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced the appointment of Scott Cooke as Operations President and welcomes his leadership, experience and passion to further advance its mission of Growth Powered by People.
Neutral
●
GlobeNewsWire
●
about 2 months ago
MEDFORD, Ore., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced it has been named to the  Fortune Global 500 for the second consecutive year, advancing to No.
Neutral
●
GlobeNewsWire
●
2 months ago
Key Highlights Record second quarter revenues of $9.8 billion Used retail GPUs increased $339, or 20%, sequentially Aftersales gross profit increased by 3.1% and gross margin was 59.2%, a 120-basis point increase, on a same-store basis Adjusted SG&A as a percent of gross profit was 68.6%, a 290-basis point improvement sequentially Financing Operations achieved record income of $37 million and r...
Neutral
●
GlobeNewsWire
●
4 months ago
MEDFORD, Ore., June 09, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced that it ranked No.
Neutral
●
GlobeNewsWire
●
4 months ago
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class an...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today